Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein

Leukemia

Volumn 20, Issue 3, 2006, Pages 426-432

  DiMartino, Jorge F ^a   Lacayo, N J ^b   Varadi, M ^a   Li, L ^a   Saraiya, C ^b   Ravindranath, Y ^c   Yu, R ^b   Sikic, B I ^b   Raimondi, S C ^d   Dahl, G V ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute myeloid leukemia; DNA methylation; Matricellular glycoproteins; MLL

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; OSTEONECTIN; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CONTROLLED STUDY; DRUG TARGETING; GENE REARRANGEMENT; GENE SILENCING; GENE TRANSLOCATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN TARGETING; SENSITIVITY ANALYSIS;

EID: 33644503560     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404102     Document Type: Article

References (40)

1. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003; 102: 2395-2402.
2. Taichman RS. Blood and bone: Two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005; 105: 2631-2639.
3. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841.
4. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846.
5. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 2005; 201: 1781-1791.
6. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005; 106: 1232-1239.
7. Framson PE, Sage EH. SPARC and tumor growth: Where the seed meets the soil? J Cell Biochem 2004; 92: 679-690.
8. Yan Q, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999; 47: 1495-1506.
9. Brekken RA, Sage EH. SPARC, a matricellular protein: At the crossroads of cell-matrix communication. Matrix Biol 2001; 19: 816-827.
10. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003; 22: 5021-5030.
11. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001; 159: 609-622.
12. Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 1996; 12: 1895-1901.
13. Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW. Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat 2002; 75: 73-85.
14. Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A et al. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 2002; 62: 7357-7363.
15. Puolakkainen PA, Brekken RA, Muneer S, Sage EH. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2004; 2: 215-224.
16. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 2003; 111: 487-495.
17. Le Beau MM, Espinosa III R, Neuman WL, Stock W, Roulston D, Larson RA et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA 1993; 90: 5484-5488.
18. Kelm Jr RJ, Mann KG. Human platelet osteonectin: Release, surface expression, and partial characterization. Blood 1990; 75: 1105-1113.
19. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 2004; 104: 2646-2654.
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
21. Drexler HG, MacLeod RA. Leukemia-lymphoma cell lines as model systems for hematopoietic research. Ann Med 2003; 35: 404-412.
22. DiMartino JF, Cleary ML. MLL rearrangements in human malignancies: lessons from clinical and biological studies. Br J Haematol 1999; 106: 614-626.
23. Hess JL. Mechanisms of transformation by MLL. Crit Rev Eukaryot Gene Expr 2004; 14: 235-254.
24. Daser A, Rabbitts TH. Extending the repertoire of the mixedlineage leukemia gene MLL in leukemogenesis. Genes Dev 2004; 18: 965-974.
25. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605-1616.
26. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004; 104: 3679-3687.
27. Funk SE, Sage EH. The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 2648-2652.
28. Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005; 115: 1492-1502.
29. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM et al. Methylation of the 5′ CpG island of the p16/ CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55: 4531-4535.
30. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
31. Stirzaker C, Song JZ, Davidson B, Clark SJ. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004; 64: 3871-3877.
32. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002; 21: 1048-1061.
33. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004; 23: 138-149.
34. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003; 3: 89-95.
35. Francki A, McClure TD, Brekken RA, Motamed K, Murri C, Wang T et al. SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 2004; 91: 915-925.
36. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003; 14: 3977-3988.
37. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 1998; 273: 29635-29640.
38. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with plateletderived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci USA 1992; 89: 1281-1285.
39. Hasselaar P, Sage EH. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem 1992; 49: 272-283.
40. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-313.